Giant Biogene Holding SEHK 2367 Valuation Check After Weaker Earnings And Adjusted Dividends

Simply Wall St.03-28

Giant Biogene Holding (SEHK:2367) released full year 2025 results, reporting revenue and net income below the prior year. The company also proposed a reduced final ordinary dividend alongside a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622544805?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278","is_english":true,"pubTime":"2026-03-28 02:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622544805","market":"hk","top_or_hot":-1,"title":"Giant Biogene Holding SEHK 2367 Valuation Check After Weaker Earnings And Adjusted Dividends","media":"Simply Wall St.","content":"<div>\n<p>Giant Biogene Holding (SEHK:2367) released full year 2025 results, reporting revenue and net income below the prior year. The company also proposed a reduced final ordinary dividend alongside a ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/household/hkg-2367/giant-biogene-holding-shares/news/giant-biogene-holding-sehk-2367-valuation-check-after-weaker\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Giant Biogene Holding SEHK 2367 Valuation Check After Weaker Earnings And Adjusted Dividends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGiant Biogene Holding SEHK 2367 Valuation Check After Weaker Earnings And Adjusted Dividends\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-28 02:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/household/hkg-2367/giant-biogene-holding-shares/news/giant-biogene-holding-sehk-2367-valuation-check-after-weaker><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Giant Biogene Holding (SEHK:2367) released full year 2025 results, reporting revenue and net income below the prior year. The company also proposed a reduced final ordinary dividend alongside a ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/household/hkg-2367/giant-biogene-holding-shares/news/giant-biogene-holding-sehk-2367-valuation-check-after-weaker\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999004311.SGD","symbol_name":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","start_time":0,"source_url":"https://simplywall.st/stocks/hk/household/hkg-2367/giant-biogene-holding-shares/news/giant-biogene-holding-sehk-2367-valuation-check-after-weaker","article_id":"2622544805","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/household/hkg-2367/giant-biogene-holding-shares/news/giant-biogene-holding-sehk-2367-valuation-check-after-weaker","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622544805","pubTimestamp":1774635277,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Giant Biogene Holding (SEHK:2367) released full year 2025 results, reporting revenue and net income below the prior year. The company also proposed a reduced final ordinary dividend alongside a separate special dividend for shareholders.\nSee our latest analysis for Giant Biogene Holding.\nDespite the latest earnings release and the mix of a reduced ordinary dividend with a separate special dividend, Giant Biogene Holding’s 1-year total shareholder return of 56.34% decline and 3-year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","BK1207":"个人用品","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","02367":"巨子生物","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC"},"translate_title":"Biant Biogene Holding SEHK 2367在盈利疲软和股息调整后进行估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"02367":0.9},"content_text":"Giant Biogene Holding (SEHK:2367) released full year 2025 results, reporting revenue and net income below the prior year. The company also proposed a reduced final ordinary dividend alongside a separate special dividend for shareholders. See our latest analysis for Giant Biogene Holding. Despite the latest earnings release and the mix of a reduced ordinary dividend with a separate special dividend, Giant Biogene Holding’s 1-year total shareholder return of 56.34% decline and 3-year total shareholder return of 36.87% decline show that longer term performance has been weak. The recent 1-day share price return of 1.54% only partly offsets a 30-day share price return of 9.09% decline and a year to date share price return of 15.20% decline, suggesting sentiment has been softening rather than building momentum at the current share price of HK$29.02. If this earnings and dividend update has you rethinking where growth and income might come from next, it could be a good moment to broaden your search with 94 top founder-led companies With earnings and dividends under pressure and the share price trading well below some valuation estimates, the key question is whether Giant Biogene is now trading at a discount or if the market is already pricing in future growth. AdvertisementPrice-to-Earnings of 14.2x: Is it justified? On a P/E of 14.2x at a last close of HK$29.02, Giant Biogene is flagged as good value compared to peers, the wider Asian personal products industry and an estimated fair P/E of 18.6x. The P/E multiple compares the current share price with earnings per share and is a quick way to see how much the market is paying for each unit of profit. For a profitable, branded personal products business focused on recombinant collagen and functional skincare in Mainland China, this lens helps you gauge how the market is weighing its earnings profile against other listed names. Here, the data suggests the market is pricing Giant Biogene’s earnings lower than both the peer group average P/E of 15x and the Asian personal products industry average of 21x. If sentiment were to shift toward the estimated fair P/E of 18.6x, that would be a higher earnings multiple than today, which is a level the share price could potentially move towards if investors reassess how they value the company’s profit stream. Explore the SWS fair ratio for Giant Biogene Holding Result: Price-to-Earnings of 14.2x (UNDERVALUED) However, the weak 1-year and 3-year total returns, alongside revenue and net income pressure, suggest sentiment could stay fragile if operating trends or dividends soften further. Find out about the key risks to this Giant Biogene Holding narrative. Another View: Cash Flows Paint an Even Cheaper Picture While the P/E of 14.2x suggests Giant Biogene is attractively priced, the SWS DCF model indicates the shares at HK$29.02 trade below an estimated future cash flow value of HK$58.96. If earnings unfold as modeled, is the market leaving too much on the table? Look into how the SWS DCF model arrives at its fair value. 2367 Discounted Cash Flow as at Mar 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Giant Biogene Holding for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 236 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps With sentiment in this article leaning cautious, it may be useful to act quickly and test the numbers yourself before views settle in one direction. To see what the market is currently optimistic about, take a closer look at the company's 3 key rewards Looking for more investment ideas? If you are reassessing Giant Biogene, this is a good time to widen your opportunity set and line up a few fresh ideas before the next move.  Target dependable cash generators by reviewing companies in the solid balance sheet and fundamentals stocks screener (381 results) so you are not relying on fragile finances when conditions get tougher. Hunt for mispriced opportunities by scanning the 236 high quality undervalued stocks and see which businesses the market may be overlooking right now. Prioritise resilience and sleep better at night by focusing on the 284 resilient stocks with low risk scores instead of taking on more uncertainty than you intended.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622544805","isCrawlerRequest":true}